ADHD Non-Stimulant Medications Step Therapy Program
|
|
- Bathsheba Paul
- 5 years ago
- Views:
Transcription
1 ADHD Non-Stimulant Medications Step Therapy Program Policy Number: Last Review: 7/2018 Origination: 07/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will BCBSKC will provide coverage for brand name non-stimulant when the following criteria are met. The brand name medications affected are: Strattera (atomoxetine capsules Eli Lilly and Company) Intuniv (guanfacine extended-release tablets Shire Pharmaceuticals) Kapvay (clonidine hydrochloride extended-release tablets Shionogi Pharma, generics) When Policy Topic is covered A step therapy program has been developed to encourage use of a Step 1 product prior to a Step 2 product. If the step therapy rule is not met for a Step 2 agent at the point of service, coverage will be determined by the step therapy criteria below. All approvals are provided for 1 year in duration. Note: Generic guanfacine extended-release tablets and generic clonidine extended-release tablets are not included in either Step 1 or Step 2 of this program. Automation: This program looks back for one Step 1 medication in the previous 130 days. If criteria for use of one stimulant medication within the last 130 days (automated) are not met at the point of service, coverage will be determined by the step therapy criteria below. Step 1: generic atomoxetine capsules, stimulant medications (amphetamine and methylphenidate/dexmethylphenidate products) Amphetamines (Note: This is not an all inclusive list.) Amphetamine sulfate tablets (Evekeo ) Amphetamine extended-release orally disintegrating tablets (Adzenys XR-ODT ) Amphetamine extended-release oral suspension (Dyanavel XR, Adzenys ER ) Mixed amphetamine salts [dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate, amphetamine aspartate] immediate-release tablets (Adderall, generics)/ extended-release capsules (Adderall XR, generics) Dextroamphetamine immediate release tablets (Dexedrine, Zenzedi, generics)/sustained-release capsules (Dexedrine Spansules, generics) Dextroamphetamine sulfate oral solution (ProCentra, generics) Methamphetamine tablets (Desoxyn, generics) Lisdexamfetamine capsules (Vyvanse ) Methylphenidate/dexmethylphenidate (Note: This is not an all inclusive list.) methylphenidate extended-release tablets or capsules (Aptensio XR, Concerta, Metadate CD, Metadate ER, Ritalin LA, Ritalin-SR, generics) methylphenidate immediate release tablets, oral solution, and chewable tablets (Ritalin, Methylin, Methylin Chewable, generics) dexmethylphenidate immediate-release tablets (Focalin, generics)
2 dexmethylphenidate extended-release capsules (Focalin XR, generics) methylphenidate transdermal system (Daytrana ) methylphenidate extended-release oral suspension (Quillivant XR, QuilliChew ER ) Step 2: Strattera (brand), Intuniv (brand), Kapvay (brand) CRITERIA Exceptions for a Step 2 agent can be made for patients with one of the following conditions/situations: 1. If the patient has tried a Step 1 agent, then authorization for a Step 2 agent may be given. 2. No other exceptions are recommended. When Policy Topic is not covered The use of brand name non-stimulant medications is considered investigational for all other indications. Considerations ADHD non-stimulant medications require prior authorization through the Clinical Pharmacy Department. This Blue Cross and Blue Shield of Kansas City policy Statement was developed using available resources such as, but not limited to: Food and Drug Administration (FDA) approvals, Facts and Comparisons, National specialty guidelines, Local medical policies of other health plans, Medicare (CMS), Local providers. Description of Procedure or Service Attention-deficit hyperactivity disorder (ADHD) is a neurobehavioral disorder that typically begins in childhood and often persists into adulthood. 1 ADHD is characterized by developmentally inappropriate levels of inattention and hyperactivity resulting in functional impairment in academic, family, and social settings. ADHD is the most commonly diagnosed neurobehavioral disorder of childhood. Treatment The American Academy of Pediatrics (AAP) clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD in children and adolescents (2011) indicate that stimulants have the most evidence for efficacy and safety in the treatment of ADHD, and remain the first choice of medication treatment. 2-3 Individuals may respond to one stimulant but not to another, and it cannot be predicted which stimulant will be best in an individual. Therefore, if a trial with one group is unsuccessful (poor efficacy or adverse events [AEs]), a trial on a medication from the other group should be undertaken. At least onehalf of the patients whose symptoms fail to respond to one stimulant medication may have a positive response to the alternative medication. The dose of medication should be titrated to achieve maximum benefit with minimum AEs. More than 70% of children and youth with ADHD respond to one of the stimulant medications at an optimal dose when a systematic trial is used. Titration to maximum doses that control symptoms without AEs is recommended instead of titration strictly on a mg-per-kg basis. The 2006 Texas Children s Medication Algorithm for the pharmacotherapy of ADHD 4 and the 2007 American Academy of Child and Adolescent Psychiatry (AACAP) ADHD treatment guidelines 5 recommend stimulants as first line treatment for ADHD followed by a trial of another stimulant if the first stimulant is not effective. 4-5 The Texas Children s Medication Algorithm 4 states that Strattera may be considered in patients after one stimulant trial if the patient experienced severe AEs. According the AACAP guidelines, if patients do not achieve satisfactory treatment response to stimulants or Strattera, use of other medications may be considered. 5 The guidelines indicate that alpha-agonists (guanfacine immediate-release, clonidine) are often used in the treatment of ADHD
3 even though they were not approved by the Food and Drug Administration (FDA) at the time of publication. However, alpha-agonists (along with other second-line agents) have effect sizes considerably less than those of the first-line agents and comparable with behavioral therapy. Alphaagonists are widely used for ADHD itself, for comorbid aggression, or to combat AEs such as tics or insomnia, although data are lacking. These guidelines also indicate that children with ADHD and a comorbid tic disorder, on average, show a decline in tics when treated with a stimulant. If a patient has treatment emergent tics during a trial of a stimulant, an alternative stimulant or a nonstimulant should be tried. If the patient s ADHD symptoms only respond to a stimulant that induces tics, adding an alpha-agonist is recommended. The Texas Children s Medication Algorithm states that for ADHD an alpha agonist may be used after a trial of two stimulants, Strattera (atomoxetine capsules), bupropion, and a tricyclic antidepressant (TCA). 4 Hence, alpha agonists are the last stage in the algorithm. For ADHD with comorbid tic disorders, stimulant monotherapy is still first-line therapy. However, if tics continue to impair, an alpha agonist may be added. Several stimulants are approved for the treatment of ADHD in adolescents, as well as adults. 6 Strattera is indicated for the treatment of ADHD in children 6 years of age, adolescents, and adults. 7 Limited data are available with Strattera in children < 6 years of age. 8 Overall, studies with Strattera in ADHD have been short term (about 3 to 10 weeks); a 12 month trial in children; an 18 month trial in children and adolescents; and a 97 week open-label study in adults have been published In contrast, the stimulants have been well studied, especially in children with ADHD, and their safety and efficacy for long-term therapy are well established Two alpha agonists are currently approved for the treatment of ADHD: Intuniv (guanfacine extendedrelease tablets) and Kapvay. Both of these agents are approved for use in children and adolescents aged 6 to 17 years No controlled studies have studied Intuniv or Kapvay in children < 6 years of age or adults. The effectiveness of Intuniv and Kapvay for longer-term use (more than 9 weeks and 5 weeks, respectively) has not been systematically evaluated in controlled trials. However, long-term efficacy of Intuniv was assessed in two 24-month open-label extension studies Rationale Comparative Efficacy Intuniv or Kapvay have not been compared to any of the stimulants in head-to-head studies. In total, there are six published studies comparing Strattera to a stimulant. More well-designed studies are needed that directly compare Strattera to methylphenidate and amphetamine-type products. A review article (published in 2006) evaluated five of the head-to-head comparison studies between Strattera and stimulants. 21 Overall, there was no difference between Strattera and methylphenidate immediate-release in efficacy as measured by ADHD rating scale total score; methylphenidate osmotic oral release system (OROS) showed significantly greater improvement at Weeks 1 and 2 compared to Strattera and more patients treated with methylphenidate OROS were considered responders; and both Strattera and mixed amphetamine salts (MAS) extended-release (XR) showed significant improvements at endpoint; however, Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) scores were significantly better with MAS XR. Tics/Tourette s Syndrome According to product labeling, methylphenidate is contraindicated in patients with motor tics or with a family history or diagnosis of Tourette s syndrome. 27 However, controlled trials have not found that methylphenidate worsens motor tics in children with ADHD with or without Tourette s syndrome. 14,28 In uncontrolled studies with Concerta (methylphenidate extended-release), the cumulative incidence of new onset of tics was 9% after 27 months in one study and 1% in a second study with a treatment period of up to 9 months. 27 In three controlled studies in children with ADHD, the percentage of patients experiencing tics was not significantly different between Concerta (4.0%), methylphenidate
4 three times daily (2.3%), and placebo (3.7%) [P = ]; none of the patients had Tourette s syndrome and those with mild or moderate tics could enroll. 29 Most patients who reported tics during the studies had a prior history of tics. According to product labeling, amphetamines may exacerbate motor and phonic tics and Tourette s syndrome. 30 In a review of seven studies that compared stimulants to placebo or with other medications, there was no increase in tics in children who received stimulants. 31 Studies that compared Strattera with placebo in ADHD did not specify whether patients with motor tics or with a family history or diagnosis of Tourette s syndrome were included or excluded One 18- week, randomized, double-blind, placebo-controlled study 38 enrolled 148 children with ADHD and concurrent Tourette syndrome or chronic motor tic disorder (of mostly mild to moderate severity). The primary objective of the study was to test the hypothesis that Strattera does not worsen tics (noninferiority study design). Both treatment groups decreased tic severity from baseline and Strattera was found to be non-inferior to placebo. In both open label trials that compared Strattera with methylphenidate as well as the controlled trial that compared Strattera with Adderall XR, patients with motor tics or a family history of Tourette s syndrome were excluded; motor and vocal tics were not reported as adverse events Tics are not included as an AE in the product labeling for Strattera. 7 However, there are case reports of children with ADHD who had developed tics on stimulant medications and in whom tics reappeared or were exacerbated on Strattera, 38 and case reports of worsening of tics with Strattera. 39 Practice guidelines for ADHD state that the effects of medication on tics is unpredictable, and the presence of tics before or during medical management of ADHD is not a contraindication to the use of stimulant drugs. 2,7 The 2007 AACAP ADHD treatment guidelines state that Strattera may be considered first-line medication for individuals with ADHD and tics. 2 In treating patients with ADHD and tic disorder, the 2006 Texas Children s Medication Algorithm for the pharmacotherapy of ADHD still recommends first line treatment with a stimulant. 5 However, if tics continue to impair, an alpha agonist may be added to stimulant therapy. Seizures According to a warning in the product labeling, amphetamine and methylphenidate may lower the seizure threshold in patients with a prior history of seizures, in patients with prior electroencephalogram (EEG) abnormalities in absence of seizures, and very rarely, in the absence of history of seizures and no prior EEG evidence of seizures. 27,30 Many studies have reported that methylphenidate is safe in children with active or well-controlled epilepsy and that methylphenidate does not increase the risk of developing seizures in children with ADHD Practice guidelines for ADHD also state that methylphenidate has not caused an increase in seizure frequency or severity when it is added to appropriate anticonvulsant medications. 14 Although amphetamine and methylphenidate are not contraindicated in children with pre-existing epilepsy, it is important to monitor seizure frequency when initiating therapy. 27,30 Strattera has not been systematically evaluated in controlled trials in patients with seizure disorders. During the clinical development program, seizures occurred in 0.2% of children (mean age 10 years). 7 Placebo-controlled efficacy and safety trials with Strattera excluded patients with a history of seizures 32,34 or other serious medical illnesses. 22,33,35-36 Seizures have been reported with Strattera in the postmarketing period. 7 The postmarketing seizure cases include patients with preexisting seizure disorders and those with identified risk factors for seizures, as well as patients with neither a history of nor identified risk factors for seizures. The exact relationship between Strattera and seizures is difficult to evaluate due to uncertainty about the background risk of seizures in patients with ADHD. Intuniv and Kapvay also have not been evaluated in controlled trials in patients with seizure disorders. During the clinical development programs for Intuniv and Kapvay there were no reports of seizures Cardiovascular (CV) In 2011, the FDA issued safety communications regarding medications used to treated ADHD (stimulants [methylphenidate and amphetamine products] and Strattera) and cardiovascular safety Based on large retrospective cohort studies, the FDA recommendations include: stimulant products
5 and Strattera should generally not be used in patients with serious heart problems, or for whom an increase in blood pressure or heart rate would be problematic; and, patients treated with ADHD medications should be periodically monitored for changes in heart rate or blood pressure. Methylphenidate products should generally not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems due to reports of sudden cardiac death in association with stimulants. 27 Caution should be used in treating patients with methylphenidate who have underlying medical conditions that might be compromised by increases in blood pressure or heart rate (e.g., preexisting hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia). Amphetamines are contraindicated in patients with advanced arteriosclerosis, symptomatic CV disease, moderate to severe hypertension, and hyperthyroidism. 30 Strattera is contraindicated in patients with severe CV disorders whose condition would be expected to deteriorate if they experience clinically important increases in blood pressure or heart rate (e.g., 15 to 20 mmhg in blood pressure or 20 beats per minute [bpm] in heart rate). 7 In addition, Strattera should be used with caution in patients with hypertension, tachycardia, or CV or cerebrovascular disease. In pediatric trials, patients on Strattera had a mean increase in heart rate of 5.0 bpm and 9.4 bpm for extensive and poor metabolizers, respectively, and tachycardia was an AE in 0.3% of Strattera patients vs. 0% on placebo. In adult trials, tachycardia was an AE in 1.5% of Strattera patients vs. 0.5% on placebo. In short-term, placebo-controlled clinical trials, the proportions of pediatric and adults patients having an increase in diastolic blood pressure 15 mmhg were 21.5% and 12.6%, respectively, at any one time, and 9.3% and 4.8%, respectively, at endpoint. The proportions of pediatric and adults patients having an increase in systolic blood pressure 20 mmhg were 12.5% and 12.4%, respectively, at any one time, and 4.9% and 4.2%, respectively, at endpoint. The proportions of pediatric and adults patients having an increase in heart rate 20 bpm were 23.4% and 22.4%, respectively, at any one time, and 12.2% and 10.2%, respectively, at endpoint. Orthostatic hypotension and syncope have also been reported in patients taking Strattera; therefore, Strattera should be used with caution in any condition that may predispose patients to hypotension, or conditions associated with abrupt heart rate or blood pressure changes. Intuniv and Kapvay should be used with caution in patients with a history of hypotension, heart block, bradycardia, CV disease, or syncope because it can decrease blood pressure and heart rate These alpha agonists should also be used with caution in patients treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope. Patients should be advised to avoid becoming dehydrated or overheated. In the pediatric, short-term, controlled trials with Intuniv, the maximum mean changes from baseline in systolic blood pressure, diastolic blood pressure, and pulse were -5 mmhg, -3 mmhg, and -6 bpm, respectively. 16 Hypotension was reported as an AE for 7% of the Intuniv group vs. 3% of the placebo group. Orthostatic hypotension was reported for 1% and 0% on the Intuniv and placebo groups, respectively. In pediatric patients that completed 5 weeks of treatment in a controlled, fixed-dose, monotherapy trial with Kapvay, the maximum placebo-subtracted mean changes in systolic blood pressure, diastolic blood pressure, and heart rate for the 0.2 and 0.4 mg/day doses were -4.0 and -8.8 mmhg, -4.0 and mmhg, and -4.0 and -7.7 bpm, respectively. 17 Bradycardia was reported as an AE for 4% of the Kapvay 0.4 mg/day group, and 0% for both the Kapvay 0.2 mg/day and placebo groups. Comorbid Anxiety Anxiety disorders reportedly occur in up to one third of patients with ADHD. 2 There are data showing treatment with Strattera, either as monotherapy or in combination with a selective serotonin receptor antagonist (SSRI), significantly reduces ADHD and anxiety symptom scores Initial reports showed an increased placebo response rate, a greater incidence of side effects, and smaller improvements on cognitive tests in children with ADHD and comorbid anxiety disorder treated with methylphenidate. 14 However, more recent controlled studies do not support these findings ,50 There are data from recent controlled trials showing improvement in anxiety symptoms as well as
6 ADHD symptoms in children treated with methylphenidate ,51 Treatment guidelines state that the contraindication of anxiety disorder in the methylphenidate prescribing information has not been supported by data from recent randomized, controlled trials which actually showed children with comorbid anxiety disorder to improve on methylphenidate. 4-5,14 Anxiety is not listed as a contraindication, warning, or precaution in amphetamine product labeling. A trial with a stimulant is one of the first-line treatment options in this patient population. If the stimulant improves ADHD symptoms but the anxiety symptoms remain, an SSRI or other anti-anxiety medication should be added. 14 In a recently published small, double-blind, placebo-controlled study there was no improvement in residual anxiety symptoms when the SSRI fluvoxamine was added to existing methylphenidate therapy compared to placebo. 52 As a result of this study, the 2007 AACAP ADHD treatment guidelines 5 now state that using Strattera for the treatment of ADHD with comorbid anxiety is a viable alternative approach to the practice of first treating with a stimulant and then adding an SSRI if necessary. In treating patients with ADHD and comorbid anxiety, the 2006 Texas Children s Medication Algorithm for the pharmacotherapy of ADHD recommends either first treating the ADHD with a stimulant and then adding an SSRI to treat residual anxiety symptoms or treating with Strattera initially; either approach is considered acceptable as initial treatment. 4 References: 1. National Survey of Children s Health (NSCH). Data Resource Center for Child and Adolescent Health. Available at: Accessed on: February 21, American Academy of Pediatrics. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128: American Academy of Pediatrics. Supplemental Information. Implementing the key action statements: an algorithm and explanation for process of care for the evaluation, diagnosis, treatment, and monitoring of ADHD in children and adolescents. Pediatrics. Published online: October 16, Available at: Accessed on February 21, Pliszka SR, Crismon L, Hughes CW, et al. The Texas children s medication algorithm project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2005;45(6): American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7): Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; Available at Accessed on: February 21, Search terms: amphetamine, methylphenidate, and lisdexamfetamine. 7. Strattera capsules [prescribing information]. Indianapolis, IN: Eli Lilly and Company; February 20, Kratochvil CJ, Vaughan BS, Stoner JA, et al. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. Pediatrics. 2011;127:e862-e Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43: Buitelaar JK, Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry. 2007;61: Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr. 2006;149: Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(8):
7 13. Adler LA, Spencer TJ, Milton DR, et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry. 2005;66: Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2 Suppl):26S-49S. 15. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiaty. 1999;56: Intuniv extended-release tablets [prescribing information]. Wayne, PA: Shire US Inc; August Kapvay extended-release tablets, oral [prescribing information]. Atlanta, GA: Shionogi Pharma, Inc.; February Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13: Sallee FR, Lyne A, Wigal T, McGough JJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19: Yildiz O, Sismanlar SG, Memik NC, Karakaya I, Agaoglu B. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive function. Child Psychiatry Hum Dev. 2011;42: Gibson A, Bettinger TL, Patel NC, Crismon ML. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother. 2006;40(6): Wigal SB, Wigal TL, McGough JJ, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR ) and atomoxetine (Strattera ) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord. 2005;9(1): Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41: Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther. 2005;22(5): Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165: Sangal RB, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep. 2006;29(12): Concerta extended release tablets [prescribing information]. Titusville, NJ: Janssen Pharmaaceuticals, Inc.; December Roessner V, Robatzek M, Knapp G, Banaschewski T, Rothenberger A. First-onset tics in patients with attention-deficit/hyperactivity disorder: impact of stimulants. Dev Med Child Neurol. 2006;48: Palumbo D, Spencer T, Lynch J, et al. Emergence of tics in children with ADHD: impact of oncedaily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol. 2004;14: Adderall XR extended release capsules [prescribing information]. Newport, KY: Shire US Inc.; December Jadad AR, Boyle M, Cunningham C, et al. Treatment of attention deficit/hyperactivity disorder. Evidence Report/Technology Assessment No. 11. Rockville, MD: Agency for Healthcare Research and Quality; AHRQ Pub. No. 00-E Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatr. 2002;159:
8 34. Biederman J, Heiligenstein JH, Faries DE, et al. Efficacy of atomoxetine versus placebo in schoolage girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110:e Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53: Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114:e Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65: Lee TS, Lee TD, Lombroso PJ, et al. Atomoxetine and tics in ADHD. J Am Acad Child Adolesc Psychiatry. 2004;43: Feldman PD, Ruff DD, Allen AJ. Atomoxetine and tics in ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44: Schubert R. Attention deficit disorder and epilepsy. Pediatr Neurol. 2005;32: Gucuyener K, Erdemoglu AK, Senol S, et al. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol. 2003;18: Tan M, Appleton R. Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy. Arch Dis Child. 2005;90: Aldenkamp AP, Arzimanoglou A, Reijs R, Van Mil S. Optimizing therapy of seizures in children and adolescents with ADHD. Neurology. 2006;67(Suppl 4):S49-S FDA Drug Safety Communication: Safety review update of medications used to treat attentiondeficit/hyperactivity disorder (ADHD) in children and young adults. November 1, Available at: Accessed on February 21, FDA Drug Safety Communication: Safety review update of medications used to treat attentiondeficit/hyperactivity disorder (ADHD) in adults. December 12, Available at: Accessed on February 21, Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306:E1-E Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;356: Kratochvil CJ, Newcorn JH, Arnold E, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9): Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attentiondeficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(9): Diamond IR, Tannock R, Schachar RJ. Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry. 1999;38(4): Abikoff H, McGough J, Vitiello B, et al. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2005;44(5) Abikoff H, McGough J, Vitiello B, et al. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2005;44(5): Berigan TR. Atomoxetine used adjunctively with selective serotonin reuptake inhibitors to treat depression. Prim Care Companion J Clin Psychiatry. 2004;6: Carpenter LL, Milosavljevic N, Jordan JD, Schecter JM, Tyrka AR, Price LH. Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry. 2005;66: Michelson D, Adler LA, Amsterdam JD, et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68: Shatkin JP. Atomoxetine for the treatment of pediatric nocturnal enuresis. J Child Adolesc Psychopharmacol Fall;14(3):
9 57. Berigan T. The use of atomoxetine adjunctively in fibromyalgia syndrome. Can J Psychiatry. 2004;49: Billing Coding/Physician Documentation Information N/A Brand name non-stimulant medications are considered a pharmacy benefit. Additional Policy Key Words Policy Number: Policy Implementation/Update Information 07/2014 New Policy titled ADHD Non-Stimulant Medications Step Therapy Program 07/2015 Annual Review- no changes 07/2016 Annual Review- no changes 07/2017 Annual Review- no changes 07/2018 Annual review no changes State and Federal mandates and health plan contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The medical policies contained herein are for informational purposes. The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents Blue KC and are solely responsible for diagnosis, treatment and medical advice. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, or otherwise, without permission from Blue KC.
generics) ER, Methylin and generic) prior authorization
ADHD Non-Stimulant Medications Step Therapy Program Policy Number: 5.01.596 Origination: 07/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for brand name non-stimulant
More informationADHD Stimulant Step Therapy Program
ADHD Stimulant Step Therapy Program Policy Number: 5.01.592 Last Review: 7/2018 Origination: 7/2017 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationAttention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6
in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,
More informationPHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
DYANAVEL XR (amphetamine) extended-release oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationQUANTITY LIMIT CRITERIA
DRUG CLASS (ADHD) AGENTS BRAND NAME (generic) QUANTITY LIMIT CRITERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER ADDERALL (amphetamine mixture) ADDERALL XR (amphetamine extended-release mixture) ADZENYS
More informationDrug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative
More informationClinical Policy: Atomoxetine (Strattera) Reference Number: CP.PST.17 Effective Date:
Clinical Policy: (Strattera) Reference Number: CP.PST.17 Effective Date: 08.01.17 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationGA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy
Override(s) Prior Authorization ADHD Narcolepsy Approval Duration 1 year *Louisiana, Washington and Maryland Medicaid See State Specific Information Below Medications Atomoxetine: Strattera generic Clonidine
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PMA_10.11.7 Effective Date: 07.16 Last Review Date: 04.18 Line of Business: Cenpatico Medicaid Arizona Revision Log See Important Reminder at the end of this policy
More informationPharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: November 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationClinical Policy: CNS Stimulants Reference Number: CP.PMN.XX Effective Date: Last Review Date: Line of Business: Commercial, Medicaid
Clinical Policy: Reference Number: CP.PMN.XX Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: CNS Stimulants Reference Number: CP.PMN.92 Effective Date: Last Review Date: Line of Business: Commercial, Medicaid
Clinical Policy: Reference Number: CP.PMN.92 Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCentral Nervous System Stimulants Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Central Nervous System Stimulants Drug Class Prior Authorization Protocol This policy has been developed through
More informationPharmacy Medical Necessity Guidelines: CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationOVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS
Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationPharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationScottish Medicines Consortium
Scottish Medicines Consortium atomoxetine capsules 10 mg to 60 mg (Strattera ) (153/05) Eli Lilly and Company Ltd No. 4 February 2005 The Scottish Medicines Consortium has completed its assessment of the
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs. Program Number 2017 P Prior Authorization/Notification CNS Stimulants
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1020-6 Program Prior Authorization/Notification CNS Stimulants Medication Adderall* (amphetamine-dextroamphetamine mixed salts),
More informationAD/HD is a mental disorder, and it often lasts from
short version10 WHAT WE KNOW Managing Medication for Adults with AD/HD AD/HD is a mental disorder, and it often lasts from childhood into adulthood. Medication is the basic part of treatment for adults.
More informationADHD Medications: Basics. David Benhayon MD, PhD
ADHD Medications: Basics David Benhayon MD, PhD Goals & Objectives Understand basic classes of stimulants and equivalents Be exposed to role of nonstimulant alternatives Discuss the role of therapy in
More informationThe Use of ADHD Medication in the Pediatric Population
The Use of ADHD Medication in the Pediatric Population Shirin Madzhidova, PharmD Pediatric Pharmacotherapy Fellow Nova Southeastern University Objectives Discuss the importance of treatment with medications
More information35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: ADHD Medications P&T DATE 12/13/2017 CLASS: Psychiatric Disorders REVIEW HISTORY 12/16, 9/15, 5/12, 5/10, LOB: MCL (MONTH/YEAR)
More informationAmphetamines
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.24 Subject: Amphetamines Page: 1 of 6 Last Review Date: December 8, 2017 Amphetamines Description
More informationBig Lots Behavioral Health. Prescribing Guidelines for Behavioral Health
Big Lots Behavioral Health Prescribing Guidelines for Behavioral Health Prescribing for Behavioral Health This document was developed by Nationwide Children s Hospital in conjunction with Partners For
More informationADHD Medications Table
Stimulants are the first line treatment of choice for ADHD followed by Non-Stimulants, then off-label medications. We are providing this list of medications so that you can be familiar with the common
More informationCerebral Stimulant and ADHD Drugs Prior Authorization Request
Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 Cerebral Stimulant and ADHD Drugs Prior Authorization
More informationAmphetamines
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.24 Subject: Amphetamines Page: 1 of 6 Last Review Date: September 23, 2016 Amphetamines Description
More informationJudges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
More informationPharmacotherapy of ADHD Across the Lifecycle: Stimulants
Pharmacotherapy of ADHD Across the Lifecycle: Stimulants Thomas J. Spencer, MD Massachusetts General Hospital Harvard Medical School Percent Change (Bmax/Kd) DVR Images Obtained with [ 11 C]Raclopride
More informationADHD: Management Update
4/5/17 Conflicts of Interest ADHD: Management Update I have no conflicts to disclose. Jennifer R. Walton, MD, MPH, FAAP April 7, 2017 ADHD: DSM-5 Definition Objectives To briefly review ADHD diagnostic
More informationATOMOXETINE AND METHYLPHENIDATE TREATMENT IN ADHD
20 ACTA MEDICA MARTINIANA 2015 15/1 DOI: 10.1515/acm-2015-0003 ATOMOXETINE AND METHYLPHENIDATE TREATMENT IN ADHD Snircova E 1,2, Hrtanek I 1,2, Kulhan T 1,2, Nosalova G 1, Ondrejka I. 2 1 Department of
More informationBig Lots Behavioral Health. Prescribing Guidelines for Behavioral Health
Big Lots Behavioral Health Prescribing Guidelines for Behavioral Health Prescribing for Behavioral Health This document was developed by Nationwide Children s Hospital in conjunction with Partners For
More informationMethylphenidate Dexmethylphenidate
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 6 Last Review Date: September 15, 2017 Methylphenidate
More informationOff Label Uses: Amphetamines can be used as adjunctive therapy in the treatment of resistant depression (9).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.24 Subject: Amphetamines Page: 1 of 4 Last Review Date: June 19, 2015 Amphetamines Description Adderall
More informationBehavioral Health. Behavioral Health. Prescribing Guidelines
Behavioral Health Behavioral Health Prescribing Guidelines Attention Deficit/Hyperactivity Disorder (ADHD) Start with a first line medication, either from the methylphenidate or dextroamphetamine-amphetamine
More informationNorth Dakota Medicaid. Drug Utilization Review Board. Drug Class Review
North Dakota Medicaid Drug Utilization Review Board Drug Class Review Attention Deficit Hyperactivity Disorder (ADHD) Agents Prepared by Health Information Designs, Inc. 1 North Dakota Department of Social
More informationDrug Class Literature Scan: Attention Deficit Hyperactivity Disorder
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationClonidine extended-release tablets for the treatment of ADHD
Clonidine extended-release tablets for the treatment of ADHD Joan Daughton*, Lindsey Corr, Howard Liu & Madeline West Practice points Stimulant medications remain the first-line treatment for ADHD. Based
More informationPerspective Truth on ADHD & Medications. Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry
Perspective Truth on ADHD & Medications Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry Disclosures National Institute of Health ADHD and Aggression Study Co- Investigator
More informationMethylphenidate Dexmethylphenidate
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Methylphenidates Page: 1 of 7 Last Review Date: November 30, 2018 Methylphenidate Dexmethylphenidate
More informationParents Guide to ADHD Medications. Copyright Child Mind Institute
Copyright 2017. Child Mind Institute Children with attention-deficit hyperactivity disorder (ADHD) find it unusually difficult to concentrate on tasks, to pay attention, to sit still and to control impulsive
More informationMethylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (14).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 5 Last Review Date: December 2, 2016 Methylphenidate
More informationPAL Conference Cle Elum March 2015
Source Research Funding Books, Intellectual Property Advisor/ Consultant Speakers Bureau Employee In-kind Services (example: travel) Stock or Equity Honorarium or expenses for this presentation or meeting
More informationDose Range. Dose Schedule. Child: 5-60 mg Over 50 kg:5-100 mg Focalin, child: mg Over 50 kg: mg. Focalin: 4-5 hrs.
MEDICATIONS FOR ADHD Group Main Use Medication Brand/ Form Dose Schedule Dose Range Most Common Side Effects for Group Pros for Group Cautions for Group methylphenidate Methylin Focalin (dexmethylphenidate)
More informationEvidence-Based Pharmacotherapy. Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center
Evidence-Based Pharmacotherapy Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center CME Disclosure I have no personal financial relationships in any commercial interest related to
More informationHumberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor
The Carter Jenkins Center presents 1 Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor Emeritus of Psychiatry
More informationPharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants
AETNA BETTER HEALTH Pharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants Formulary amphetamine/dextroamphetamine IR, ER (generic
More informationDrug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Report Update 3 September 2009 Update 2: November 2007 Update 1: May 2006 Original Report: September 2005 The
More informationClinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: NH.PMN.36 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: NH.PMN.36 Effective Date: 02.09 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy
More informationChild & Adolescent Psychiatry (a brief overview)
Child & Adolescent Psychiatry (a brief overview) Lance Feldman, MD, FAPA, MBA, BSN Vice Chair Clinical Affairs, Department of Psychiatry Affiliate Clinical Assistant Professor, University of South Carolina
More informationAtomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice)
New Medicine Report Document Status Atomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice) Post Suffolk D&TC Traffic Light Decision RED Date of Last Revision 12.07.04
More informationHolistic approach in management of ADHD
Holistic approach in management of ADHD Outline Historic timeline Prevalence ADHD development Treatment modalities Current guidelines for management ADHD Historical Timeline Described in 19 th century
More informationClinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: CP.PMN.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Vyvanse) Reference Number: CP.PMN.121 Effective Date: 02.01.09 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationIndividuals with attention-deficit/hyperactivity
National Resource Center on AD HD A program of CHADD 3 WHAT WE KNOW Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience
More informationManagement of Pediatric Attention Deficit & Hyperactivity Disorder (ADHD) Clinical Practice Guideline MedStar Health
Management of Pediatric Attention Deficit & Hyperactivity Disorder (ADHD) Clinical Practice Guideline MedStar Health These guideli es are pro ided to assist physi ia s a d other clinicians in making decisions
More informationClinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: CP.PMN.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Vyvanse) Reference Number: CP.PMN.121 Effective Date: 02.01.09 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationPresented by the National Resource Center on ADHD
Presented by the National Resource Center on ADHD Timothy E. Wilens, M.D. Massachusetts General Hospital Harvard Medical School Save 25% if you join/rejoin CHADD Use Promo Code: JANA14 If you are currently
More informationADHD: A Focus On Drug Therapy
ADHD: A Focus On Drug Therapy MARY WORTHINGTON, PHARM.D., BCPS MCWHORTER SCHOOL OF PHARMACY BIRMINGHAM, ALABAMA SEPTEMBER 13, 2013 Outpatient Prescription Drug Utilization in US Children, 2002-2010 90
More informationPage: 1 of 5. Methylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (12).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.25 Page: 1 of 5 Last Review Date: June 19, 2015 Description Concerta / Daytrana / Metadate CD / Metadate
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationPsychostimulant and non-stimulant agents address the symptoms of ADHD, substantial evidence shows
Psychostimulant and non-stimulant agents address the symptoms of ADHD, substantial evidence shows Tanya E. Froehlich, MD, MS Associate Professor Department of Pediatrics Division of Developmental and Behavioral
More informationA REVIEW OF STIMULANTS FOR ADHD FOR THE PRIMARY CARE PROVIDER JAMES C. ASHWORTH MD MEDICAL DIRECTOR UNIVERSITY OF UTAH NEUROPSYCHIATRIC INSTITUTE
A REVIEW OF STIMULANTS FOR ADHD FOR THE PRIMARY CARE PROVIDER JAMES C. ASHWORTH MD MEDICAL DIRECTOR UNIVERSITY OF UTAH NEUROPSYCHIATRIC INSTITUTE OVERVIEW Review Stimulant Treatment for ADHD STIMULANTS
More informationPsychopharmacology for Treatment of ADHD and ADHD with other co-existing psychiatric condition
Psychopharmacology for Treatment of ADHD and ADHD with other co-existing psychiatric condition Presented by Cat Dang, D.O Medical Director - Insightful Minds, Inc. Objectives Evaluation process Pharmacology
More informationPharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market
More informationIndividuals with attention-deficit/hyperactivity
National Resource Center on AD HD A program of CHADD 3 WHAT WE KNOW Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience
More informationAttention Deficit Hyperactivity Disorder: Comparison of Medication Efficacy and Cost
Brigham Young University BYU ScholarsArchive All Student Publications 2014-06-20 Attention Deficit Hyperactivity Disorder: Comparison of Medication Efficacy and Cost Robert M. David Karlen E. Luthy Janelle
More informationPharmacotherapy of ADHD with Non- Stimulants
Pharmacotherapy of ADHD with Non- Stimulants Timothy E. Wilens, M.D. Chief, Division of Child and Adolescent Psychiatry, (Co)Director of Center for Addiction Medicine, Massachusetts General Hospital Massachusetts
More informationPharmacologic Management of ADHD
Pharmacologic Management of ADHD CHADD Presentation April 13, 2015 Peter J Chung, MD, FAAP Developmental-Behavioral Pediatrician* Assistant Clinical Professor of Pediatrics University of California Irvine
More informationPsychopharmacology of ADHD. Copyright 2006 Neuroscience Education Institute. All rights reserved.
Psychopharmacology of ADHD Persistence (Predicted Value) Persistence of ADHD Into Adulthood 90 80 70 60 50 40 30 20 10 0 NA 10 15 20 25 30 Age at Follow-Up Syndromatic Persistence Symptomatic Persistence
More informationPL CE LIVE February 2011 Forum
February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics
More informationPEDIATRIC PHARMACOTHERAPY
PEDIATRIC PHARMACOTHERAPY Volume 22 Number 10 October 2016 T Amphetamine Orally Disintegrating Tablets: Another Option for the Treatment of Attention Deficit Hyperactivity Disorder Marcia L. Buck, PharmD,
More informationPharmacotherapy of Adult ADHD
Pharmacotherapy of Adult ADHD Thomas J. Spencer, MD Massachusetts General Hospital Harvard Medical School Disclosures Dr. Spencer receives research support from Royalties and Licensing fees on copyrighted
More informationADHD: Medications and Behavioral Interventions
ADHD: Medications and Behavioral Interventions PAL Conference June 23 rd 2018 Erin Dillon-Naftolin, MD Child and Adolescent Psychiatrist Psychiatry and Behavioral Medicine Seattle Children s Hospital Disclosures
More informationChild/Adolescent Attention-Deficit/Hyperactivity Disorder
Child/Adolescent Attention-Deficit/Hyperactivity Disorder NATIONAL GUIDELINE SUMMARY This evidence-based guideline summary is based on the 202 National Child/Adolescent Attention-Defict/ Hyperactivity
More informationStimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information
Adderall and Adderall-XR (amphetamine mixtures) Concerta (methylphenidate, controlled Dexedrine, Dexedrine Spansules (dextroamphetamine) Focalin (dexmethylphenidate) Metadate, Metadate-ER, and Metadate-CD
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR
More informationPharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners
Review Article Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners Kelly A. Brown, Sharmeen Samuel, Dilip R. Patel Department of
More informationIndividuals with attention-deficit/hyperactivity
3 W H A T W E K N O W Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience chronic problems with inattention and/or
More informationConversion from focalin xr to vyvanse
Conversion from focalin xr to vyvanse The Borg System is 100 % Conversion from focalin xr to vyvanse Sep 3, 2007. The importance of the 'conversion' dosing listed above relates to those people who may
More informationThe Benefits and Limitations of Medication Treatment for Executive Dysfunctions and ADHD
The Benefits and Limitations of Medication Treatment for Executive Dysfunctions and ADHD Damon Korb, MD Behavioral and Developmental Pediatrician Director of the Center for Developing Minds Los Gatos,
More informationADHD:Updates and Practical Suggestions
:Updates and Practical Suggestions Elizabeth Reeve MD HealthPartners Medical Group Disclosure I have no financial disclosures I may be talking about non FDA approved indications for medications Elizabeth.A.Reeve@HealthPartners.com
More informationPharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS
Workforce Safety & Insurance Revised Document Date: 07/23/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management
More informationPractical Psychopharmacology for More Complex Mental Health Presentations
MINISTRY OF CHILDREN AND YOUTH SERVICES Practical Psychopharmacology for More Complex Mental Health Presentations Part 1: Stimulants Dr. Ajit Ninan & Joel Lamoure 1 Practical Psychopharmacology for More
More informationORIGINAL INVESTIGATION. Attention-Deficit/Hyperactivity Disorder in Adults. A Survey of Current Practice in Psychiatry and Primary Care
ORIGINAL INVESTIGATION Attention-Deficit/Hyperactivity Disorder in Adults A Survey of Current Practice in Psychiatry and Primary Care Stephen V. Faraone, PhD; Thomas J. Spencer, MD; C. Brendan Montano,
More informationFocalin compared to concerta
Focalin compared to concerta Search FREE SHIPPING how does focalin compared to concerta. Free shipping, quality, privacy, secure. how does focalin compared to concerta. Compare Ritalin vs. Focalin. Focalin
More informationPHARMACOLOGIC TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS FINAL SYSTEMATIC REVIEW REPORT
PHARMACOLOGIC TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (AD) IN ADULTS FINAL SYSTEMATIC REVIEW REPORT December 2015 FINAL REPORT 2 Conflict of Interest Statement No study members report any
More informationAttention Deficit Hyperactivity Disorder
R E S E A R C H P A P E R Comparative Short term Efficacy and Tolerability of Methylphenidate and Atomoxetine in Attention Deficit Hyperactivity Disorder JASMIN GARG, PRITI ARUN AND BS CHAVAN From Department
More informationAsk The Shrink: ADHD
Ask The Shrink: ADHD Theodore A. Petti, MD Professor of Psychiatry Division of Child and Adolescent Psychiatry Robert Wood Johnson Medical School PPC Hub Psychiatrist Hackensack Meridian Hubs @ Saint Peter'
More informationFacts about ADHD drugs as treatment
Facts about ADHD drugs as treatment Common ADHD drugs as treatment Medication Stimulants Methylphenidate Dexmethylphenidate Amphetamine Non-Stimulants Straterra Guanfacine ER (Intuniv) Clonidine (Kapvay)
More informationIngrezza (valbenazine)
Ingrezza (valbenazine) Policy Number: 5.01.635 Last Review: 7/2018 Origination: 07/2017 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Ingrezza
More informationPharmacotherapy of ADHD with Non-Stimulants
Pharmacotherapy of ADHD with Non-Stimulants Timothy E. Wilens, M.D. Chief, Division of Child and Adolescent Psychiatry, (Co)Director of Center for Addiction Medicine, Massachusetts General Hospital Massachusetts
More informationAddyi (flibanserin) When Policy Topic is covered Coverage of Addyi is recommended in those who meet the following criteria:
Addyi (flibanserin) Policy Number: 5.01.605 Last Review: 10/2018 Origination: 10/2015 Next Review: 10/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Addyi when
More informationASD (hyperactivity) 3 rd LINE TREATMENT Initial liquid dose mg 2. - ADHD symptoms without sleep
Generic Name Label Name Dosing by Disorder RITALIN, RITALIN LA, CONCERTA, METADATE ER, 2 ND LINE TREATMENT 2 ND LINE TREATMENT METADATE CD, MPH ER, Initial liquid dose 1-5 mg 1,2 Initial liquid dose 1-5mg
More informationADHD and Substance Use Disorders: An Intoxicating Combination
ADHD and Substance Use Disorders: An Intoxicating Combination Timothy E. Wilens, MD Chief, Division of Child & Adolescent Psychiatry Director, Center for Addiction Medicine Massachusetts General Hospital
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More information3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM. Autism Spectrum Disorder
Cynthia King, MD Associate Professor of Psychiatry UNMSOM Autism Spectrum Disorder 1 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive
More information3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM
Cynthia King, MD Associate Professor of Psychiatry UNMSOM 1 2 Autism Spectrum Disorder 3 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive
More informationDOCUMENT NAME: lisdexamfetamine (Vyvanse ) PAGE: 1 of 5 REFERENCE NUMBER: NH.PMN.36 EFFECTIVE DATE: 02/09
PAGE: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More information